Ashok Lakhiani, MD
Child & Adolescent Psychiatry · Whitley City, KYNPI 1871543553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 32.0% of the total. 2025 is the largest year on record at $358, 5.1 times the $71 reported in 2019.
Across 18 payments — averaging $44.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$256
- AbbVie$133
- Neurocrine Biosciences, Inc.$125
- Axsome Therapeutics, Inc.$108
- Alkermes, Inc.$100
- Johnson & Johnson$30
- plus $48 from 3 others
What the payments were for
- Food & beverage$800100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $256 |
| AbbVie | 2 | $133 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $108 |
| Alkermes, Inc. | 5 | $100 |
| Johnson & Johnson | 2 | $30 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY ASIMTUFII$125
- INGREZZA$125
- VRAYLAR$112
- Auvelity$108
How this compares
$800 in reported general payments places this provider in the 60th percentile of 43 child & adolescent psychiatry providers in Kentucky.
See all child & adolescent psychiatry providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 19 | $44,357 |
| VraylarCariprazine Hcl | 20 | $29,474 |
| RexultiBrexpiprazole | 14 | $19,449 |
| TrintellixVortioxetine Hydrobromide | 24 | $11,289 |
| Olanzapine | 70 | $1,584 |
| Quetiapine Fumarate | 51 | $1,292 |
| Duloxetine Hcl | 25 | $1,229 |
| Aripiprazole | 21 | $758 |
| Risperidone | 38 | $553 |
| Mirtazapine | 24 | $533 |
| Bupropion Hcl SrBupropion Hcl | 36 | $501 |
| Hydroxyzine Hcl | 14 | $459 |
| Trazodone Hcl | 33 | $247 |
| Escitalopram Oxalate | 14 | $168 |
| Lithium Carbonate ErLithium Carbonate | 14 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $30 | $44,35719 claims |
| AbbVieVraylar | $133 | $29,47420 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $256 | $19,44914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 43 child & adolescent psychiatry providers in Kentucky.
Other child & adolescent psychiatry in Whitley City
- Ann MakarCrestview Hills$8K
- Duncan DarnellPaducah$6K
- Laura MuellerLouisville$4K
- Amber WoodLexington$3K
- Nicole GoodinLexington$3K
- Raquel VasquezLondon$3K
- Julia RoneckerCrestview Hills$2K
- Justine ChilelliCovington$2K
- Corazon ChuaLouisa$1K
- Michael McIntoshFt Wright$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.